Loading clinical trials...

Using Virtual Reality (VR) Models for Preoperative Planning | Clinical Trials | Clareo Health

COMPLETEDNA

Using Virtual Reality (VR) Models for Preoperative Planning

NCT03334344•Ceevra, Inc.

Summary

A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic partial nephrectomy) and improved patient care.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject is undergoing robotic partial nephrectomy being performed by participating surgeon
•Subject is willing to be randomized between intervention and control arms

Exclusion Criteria

•Cases involving subjects who are minors, pregnant or require an authorized representative for informed consent
•Cases in which the subject has a solitary or horseshoe kidney
•Cases in which the subject has more than two masses in the applicable kidney
•Cases involving a bilateral operation

Locations (6)

John Wayne Cancer Institute at Providence St. John's Heath Center

Santa Monica, California, United States

Mayo Clinic Florida

Jacksonville, Florida, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, United States

University of Tennessee

Knoxville, Tennessee, United States

Swedish Urology Group

Seattle, Washington, United States

Key Dates

Start Date

October 24, 2017

Primary Completion Date

February 28, 2019

Completion Date

March 18, 2019

Last Updated

August 29, 2024

Enrollment

ACTUAL participants

Conditions

Kidney CancerRenal Cell Carcinoma

Interventions

Ceevra Reveal

DEVICE

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Using Virtual Reality (VR) Models for Preoperative Planning

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery